# Coherus Oncology, Inc.: overview CHRS · Nasdaq · CIK 1512762 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/chrs.md) · [Financials](/companies/chrs/financials.md) · [Filings](/companies/chrs/filings.md) · [Insiders](/companies/chrs/insiders.md) Latest reported revenue: [$14.3m](/filings/0001104659-26-091262.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001104659-26-091262). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [6.1](/filings/0001104659-25-107852.md) | [7.7 d](/filings/0001104659-26-025308.md) | [7.6](/filings/0001104659-26-058703.md) | [10.3](/filings/0001104659-26-091262.md) | [11.6](/filings/0001104659-25-107852.md) | [12.7 d](/filings/0001104659-26-025308.md) | [12.3](/filings/0001104659-26-058703.md) | [14.3](/filings/0001104659-26-091262.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(774.2%)](/filings/0001104659-25-107852.md) | [(586.9%) d](/filings/0001104659-26-025308.md) | [(597.9%)](/filings/0001104659-26-058703.md) | [(443.6%)](/filings/0001104659-26-091262.md) | [(383.1%)](/filings/0001104659-25-107852.md) | [(359.9%) d](/filings/0001104659-26-025308.md) | [(293.7%)](/filings/0001104659-26-058703.md) | [(226.0%)](/filings/0001104659-26-091262.md) | | Net margin | % | [(177.6%)](/filings/0001104659-25-107852.md) | [(655.6%) d](/filings/0001104659-26-025308.md) | [(744.4%)](/filings/0001104659-26-091262.md) | [2903.9%](/filings/0001104659-26-091262.md) | [(307.1%)](/filings/0001104659-25-107852.md) | [(295.3%) d](/filings/0001104659-26-025308.md) | [(311.3%)](/filings/0001104659-26-091262.md) | [(144.2%)](/filings/0001104659-26-091262.md) | | Diluted EPS | $ per share | [(0.09)](/filings/0001104659-25-107852.md) | not reported | [2.57](/filings/0001104659-26-091262.md) | [2.57](/filings/0001104659-26-091262.md) | [(0.31)](/filings/0001104659-25-107852.md) | not reported | [(0.28)](/filings/0001104659-26-058703.md) | [(0.13)](/filings/0001104659-26-091262.md) | | Free cash flow | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [327](/filings/0001558370-24-003436.md) | [211](/filings/0001558370-25-003126.md) | [257](/filings/0001558370-25-003126.md) | [26.4](/filings/0001104659-26-025308.md) | [42.2](/filings/0001104659-26-025308.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(80.8%)](/filings/0001558370-24-003436.md) | [(121.7%)](/filings/0001558370-25-003126.md) | [(79.0%)](/filings/0001558370-25-003126.md) | [(756.6%)](/filings/0001104659-26-025308.md) | [(429.5%)](/filings/0001104659-26-025308.md) | | Net margin | % | [(87.9%)](/filings/0001558370-24-003436.md) | [(138.2%)](/filings/0001558370-25-003126.md) | [(92.5%)](/filings/0001558370-25-003126.md) | [108.0%](/filings/0001104659-26-025308.md) | [398.4%](/filings/0001104659-26-025308.md) | | Diluted EPS | $ per share | [(3.81)](/filings/0001558370-24-003436.md) | [(3.76)](/filings/0001558370-25-003126.md) | [(2.53)](/filings/0001558370-25-003126.md) | [0.25](/filings/0001104659-26-025308.md) | [1.43](/filings/0001104659-26-025308.md) | | Free cash flow | $m | [(38.7)](/filings/0001558370-24-003436.md) | [(243)](/filings/0001558370-25-003126.md) | [(175)](/filings/0001558370-25-003126.md) | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/chrs/insiders.md) | Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing | | --- | --- | --- | --- | ---: | ---: | ---: | --- | | 2014-11-12 | [Lilly Eli & Co](/insiders/59478.md) | Former 10% Owner | Purchase (P) | 164,963 | $13.50 | $2.2m | [Form 4](/filings/0001209191-14-067900.md) | ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Timothy G. Youngquist 2020 Irrevocable Trust](/funds/2109159.md) | 2026-06-30 | $18.3m | 13,050,623 | | Not compared | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $16.8m | 12,003,316 | | Added +1,638,242 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $8.3m | 5,949,490 | | Added +496,728 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $5.2m | 3,685,567 | | Added +563,989 | | [SAMSARA BIOCAPITAL, LLC](/funds/1744967.md) | 2026-06-30 | $4.8m | 3,428,571 | | Unchanged | | [Kohlberg Kravis Roberts & Co. L.P.](/funds/1399770.md) | 2026-06-30 | $4.2m | 3,036,076 | | Unchanged | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $3.3m | 2,382,305 | | Added +56,446 | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $3.2m | 2,259,412 | | Reduced −42,589 | | [CM Management, LLC](/funds/1841857.md) | 2026-06-30 | $2.9m | 2,100,000 | | Unchanged | | [Alyeska Investment Group, L.P.](/funds/1453072.md) | 2026-06-30 | $2.4m | 1,733,234 | | Reduced −516,766 | ## Recent filings [All 902 filings](/companies/chrs/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-29 | 08:10 ET | [8-K](/filings/0001104659-26-119912.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-119912 | | 2026-08-28 | 17:11 ET | [8-K](/filings/0001104659-26-103316.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-103316 | | 2026-08-17 | 17:28 ET | [8-K](/filings/0001104659-26-097951.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-097951 | | 2026-08-17 | 17:27 ET | [8-K](/filings/0001104659-26-097949.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001104659-26-097949 | | 2026-08-05 | 17:14 ET | [10-Q](/filings/0001104659-26-091262.md) | Quarterly report, period 2026-06-30 | 0001104659-26-091262 | | 2026-08-05 | 16:43 ET | [8-K](/filings/0001104659-26-091188.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-091188 | | 2026-06-15 | 16:40 ET | [8-K](/filings/0001104659-26-074090.md) | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0001104659-26-074090 | | 2026-06-01 | 08:30 ET | [8-K](/filings/0001104659-26-068615.md) | 5.07 Shareholder vote results | 0001104659-26-068615 | | 2026-05-11 | 16:43 ET | [10-Q](/filings/0001104659-26-058703.md) | Quarterly report, period 2026-03-31 | 0001104659-26-058703 | | 2026-05-11 | 16:16 ET | [8-K](/filings/0001104659-26-058666.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-058666 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-025308.md), filed Mar 9, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/8c66b123-6058-4651-9e26-707f6dfdbb2b) ## About the filer - CIK: 1512762 - Tickers: CHRS - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category: Accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 08:11 ET. No prices; not investment advice.